Log in
The Abraham solvation parameter approach developed at UCL has become integral to the work carried out by drug discovery teams at [text removed for publication] and other major pharmaceutical companies, as well as research and development groups at international chemical companies including Syngenta and [text removed for publication]. It enables chemists to predict physicochemical and biochemical properties of chemicals, including drugs and agrochemicals, rapidly and efficiently, without the need to conduct time-consuming experiments. The method helps drug discovery teams to identify and optimise the most promising compounds, and often results in fewer compounds being made before a candidate is selected, saving time and resources. The approach has been integrated into software used for drug discovery [text removed for publication].
The case study captures and describes the outputs and impacts arising from cumulative research on the theme of accessibility in transport and urban design. Impacts are evidenced both through the research process in terms of end-user engagement, collaborative research and real world test bed research (local communities and neighbourhoods); and through intermediary and professional/ practitioner body validation, policy-making and take up of research findings and guidance/toolkits arising. Impacts have also occurred through wider dissemination, follow-up research and collaboration both nationally and internationally.
Pre-eclampsia is a major contributor to death and disability in pregnancy. Diagnosis, based on accurate blood pressure (BP)/proteinuria determination, is limited by measurement errors and being late features of the disease. In collaboration with industry, King's College London (KCL) researchers have developed an inexpensive, accurate, simple BP device suitable for rural clinics. This device allows intervention to reduce mortality/morbidity and is currently being rolled out in a Gates Foundation project in Africa and Asia. KCL researchers have also helped the company Alere Inc. with the development of a diagnostically accurate test of placental growth factor (PlGF) in women with suspected pre-eclampsia: Alere Triage®PlGF. This demonstrates high sensitivity, superior to current tests, and following commercialisation is being adopted internationally. Their work is additionally reflected in guidelines of international standards for BP device accuracy.
Evidence about the need for and provision of health visiting services generated through research undertaken at King's College London (KCL) has underpinned major changes in national policies for health visiting. Our findings about health visitors' practice, availability and distribution of services and effectiveness in terms of parenting/child outcomes, revealed both shortfalls in provision and opportunities for improvement and led to the development of a new caseload weighting tool and funding model for service planning. The accumulated evidence from this research helped convince the UK Government in 2010 to commit to 4,200 more health visitors by 2015 — a workforce expansion of nearly 50% — in a time of austerity and restraint elsewhere in the public sector.
As a result of our discoveries of a new splice variant (ASIC1b) and a new member (ASIC4) of the ASIC family, and elucidation of their roles in pain caused by tissue acidity, several pharmaceutical companies are now working on ASIC-targeted analgesics and one company has been set up specifically to focus on this work. ASIC-related therapies for a wide variety of conditions are now in clinical trials, with substantial patient involvement. Our work has allowed new therapeutic applications to be conceived for already existing prescribed compounds, and for naturally-occurring compounds, that act on ASICs. Thus, our research on ASICs has had clinical and commercial impact.
Collaboration between Imperial College Departments of Mechanical Engineering and Surgery led to the development of active constraint robot solutions which augment surgeon skills so that joint replacement components are implanted accurately and successfully. This led to the founding of Acrobot to develop innovative surgical technologies. Acrobot was acquired by Stanmore Implants Worldwide in 2010. An orthopaedic stereotaxic instrument, based on Imperial research, obtained US Food and Drug Administration (FDA) clearance in 2013. This has led to Mako-Surgical purchasing Stanmore Implants Acrobot technology in April 2013.
Reminiscence theatre's primary goals are to improve the well-being of senior citizens and promote intergenerational dialogue. ARTA has successfully engaged 100 marginalised older people, 13 young volunteers and over 200 others since 2012. The project has created a new model of reminiscence theatre by proving that archive material can be used instead of live interviews. It has learned the strengths and weaknesses of this approach and found creative solutions to the problems. It has also given the Reminiscence Theatre Archive a long-term `living' future. Finally ARTA has disseminated good practice internationally through a website, articles, training events and conferences.
Climate change will have a profound impact on built environment performance over the next 50 years. More severe flooding and overheating will lead to more obsolete buildings and premature mortality across the UK and Europe. The research team explored the issues surrounding adaptation of the built environment to climate change, and developed a new model of built asset management that integrates adaptation decision making into the building life cycle. The model is being used by facilities managers and surveyors to produce long term asset management plans, and by central and local government policy makers to inform and develop adaptation strategies.
Research in materials modelling by the Computational Science and Engineering Group (CSEG) is helping aerospace, defence and transport companies design advanced materials and new manufacturing processes. From lightweight components like aeroengine turbine blades to the control of magnetic fields to stabilise the next generation of International Space Station levitation experiments, CSEG is supporting innovations which have:
In the assessment period, CSEG collaborated closely with leading industries in steel-making (ArcelorMittal, Corus), primary aluminium (Dubal, Rusal, Norsk-Hydro, SAMI) and lightweight structural materials for transport and aerospace (European Space Agency, Rolls-Royce).
Novel vapour sorption experimental methods for the characterisation of complex particulate materials have been developed in the Department of Chemical Engineering. This research and expertise resulted in the creation of Surface Measurement Systems Limited (SMS), whose Dynamic Vapour Sorption (DVS) and Inverse Gas Chromatography (IGC) instruments are now found in >500 laboratories around the world. They are recognised standard research and development tools in the global pharmaceutical industry (DIN 66138). SMS has contributed >270 man-years of employment and generated £27M of turnover, whilst SMS instruments have generated over £300M of economic value, over the REF period.